comparemela.com

Page 13 - Commodore Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vistagen Announces Pricing of $100 Million Underwritten Offering

Vistagen Therapeutics, Inc. , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous.

San franciscoUnited statesRiverside plazaNew yorkWilliam blairVistagen therapeutics incEquity syndicate prospectus departmentExchange commissionNicolaus company incorporatedProspectus departmentWilliam blair companyVistagen therapeuticsCommodore capitalGreat point partnersLogos capitalNantahala capital

EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate - SAB Biotherapeutics (NASDAQ:SABS)

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.

Marshall waceRd fundSessa capitalCommodore capital

SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million

SAB Biotherapeutics (SABS) Announces Private Placement of up to $130 Million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRaymond jamesEddie sullivanMarshall waceAndrew moinExchange commissionRd fundCompany board of directors theArcadia securitiesSessa capitalCommodore capitalChief executive officerManaging directorCapital marketsSecurities act

VistaGen Therapeutics (VTGN) Announces Pricing of $100 Million Underwritten Offering

VistaGen Therapeutics (VTGN) Announces Pricing of $100 Million Underwritten Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

William blairVistagen therapeutics incVistagen therapeuticsCommodore capitalGreat point partnersLogos capitalNantahala capitalSurveyor capitalDrug application

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore.

United statesRaymond jamesAndrew moinMarshall waceEddie sullivanArcadia securitiesRd fundBiotherapeutics incExchange commissionCompany board of directors theSessa capitalCommodore capitalChief executive officerManaging directorCapital marketsSecurities act

vimarsana © 2020. All Rights Reserved.